ClinicalTrials.Veeva

Menu

FT516 in Subjects With Advanced Hematologic Malignancies

Fate Therapeutics logo

Fate Therapeutics

Status and phase

Terminated
Phase 1

Conditions

Acute Myelogenous Leukemia
B-cell Lymphoma

Treatments

Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Rituximab
Drug: Bendamustine
Drug: Obinutuzumab
Drug: FT516
Drug: IL-2

Study type

Interventional

Funder types

Industry

Identifiers

NCT04023071
FT516-101

Details and patient eligibility

About

This is a Phase 1/1b dose-finding study of FT516 as monotherapy in acute myeloid leukemia (AML) and in combination with CD20 directed monoclonal antibodies in B-cell lymphoma. The study includes three stages: dose escalation, safety confirmation, and dose expansion.

Enrollment

72 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

KEY INCLUSION CRITERIA:

Diagnosis of the following:

Regimen A (FT516 monotherapy):

  • Primary Refractory AML
  • Relapsed AML defined as not in CR after 1 or more re-induction attempts; if >60 years of age, prior re-induction therapy is not required

Regimen B (FT516 + rituximab or obinutuzumab):

  • Histologically documented B-cell lymphoma expected to express CD20 who have relapsed after or failed to respond to at least on prior treatment regimen and for whom there is no available therapy expected to improve survival.

All subjects:

  • Provision of signed and dated informed consent form (ICF)
  • Age ≥18 years old
  • Stated willingness to comply with study procedures and duration
  • Presence of measurable disease

KEY EXCLUSION CRITERIA:

All subjects:

  • Females of reproductive potential who are pregnant or lactating, and males or females not willing to use a highly effective form of contraception from Screening through the end of the study
  • Eastern Cooperative Oncology Group (ECOG) Performance Status ≥2
  • Evidence of insufficient organ function
  • Receipt of therapy within 2 weeks prior to Cycle 1 Day 1 or within five half-lives, whichever is shorter; or any investigational therapy within 28 days prior to Cycle 1 Day 1
  • Currently receiving or likely to require systemic immunosuppressive therapy
  • Prior allogeneic HSCT or allogeneic CAR-T within 6 months of Cycle 1 Day 1, or ongoing requirement for systemic graft-versus-host therapy
  • Receipt of an allograft organ transplant
  • Known active central nervous system (CNS) involvement by malignancy.
  • Clinically significant cardiovascular disease
  • Clinically significant infections including: Known HIV infection; Known active Hepatitis B (HBV) or Hepatitis C (HCV) infection
  • Live vaccine <6 weeks prior to start of lympho-conditioning
  • Known allergy to human albumin and DMSO

Additional Exclusion Criteria for FT516 monotherapy Regimen: Diagnosis of promyelocytic leukemia with t(15:17) translocation

Additional Exclusion Criteria for FT516 plus monoclonal antibody Regimens: Diagnosis of Waldenstrom macroglobulinemia

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

72 participants in 4 patient groups

FT516 Monotherapy
Experimental group
Description:
FT516 monotherapy in adult subjects with r/r AML.
Treatment:
Drug: IL-2
Drug: FT516
Drug: Fludarabine
Drug: Cyclophosphamide
FT516 in Combination with Monoclonal Antibodies
Experimental group
Description:
FT516 in combination with one of the following monoclonal antibodies in adult subjects with r/r B-cell lymphoma: rituximab or obinutuzumab.
Treatment:
Drug: IL-2
Drug: Obinutuzumab
Drug: FT516
Drug: Rituximab
Drug: Fludarabine
Drug: Cyclophosphamide
FT516 in Combination with Monoclonal Antibodies on an Extended-Dosing Schedule
Experimental group
Description:
FT516 on an extended-dosing schedule in combination with one of the following monoclonal antibodies in adult subjects with r/r B-cell lymphoma: rituximab or obinutuzumab.
Treatment:
Drug: IL-2
Drug: Obinutuzumab
Drug: FT516
Drug: Rituximab
Drug: Fludarabine
Drug: Cyclophosphamide
FT516 in Combination with Monoclonal Antibodies following Bendamustine Conditioning
Experimental group
Description:
Bendamustine conditioning followed by FT516 in combination with one of the following monoclonal antibodies in adult subjects with r/r B-cell lymphoma: rituximab or obinutuzumab.
Treatment:
Drug: IL-2
Drug: Bendamustine
Drug: Obinutuzumab
Drug: FT516
Drug: Rituximab

Trial contacts and locations

7

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems